Shen Shen1, Hongfei Lou1,2, Chengshuo Wang1,2, Luo Zhang1,2,3. 1. Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. 2. Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China. 3. Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Abstract
BACKGROUND: The purpose of this study was to systematically assess the subjective and objective outcomes of macrolide therapy for chronic rhinosinusitis (CRS). METHODS: PubMed, Embase and Cochrane databases were searched for clinical trials detailing the effects of macrolide therapy in patients with CRS and published up to December 2017. Sino-Nasal Outcome Test (SNOT), endoscopic scores and computed tomography scans (CT) scores were assessed by mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval. Subgroup analyses were performed to evaluate the source of heterogeneity according to study design and geographic locations. I2 metric was used to assess the heterogeneity. RESULTS: Seven randomised clinical trials (RCTs) and four cohort trials meeting pre-determined selection criteria were enrolled in this meta-analysis. Assessment of the findings for SNOT after 12 weeks' macrolide treatment demonstrated a significant improvement in subgroup of trials in Asian patients (SMD =-0.51; 95% CI: -0.96, -0.02; P=0.04), but not in non-Asians (SMD =-0.01; 95% CI: -0.65, 0.63; P=0.98). At 12 or 24 weeks' visit no significant difference in SNOT was noted compared with control group, either in RCTs or cohort trials subgroups. However, findings for endoscopic scores were found to be significantly improved compared to placebo in the subgroup of non-RCT studies after 8 weeks (SMD =-0.77; 95% CI: -1.07, -0.46; P<0.00001) and 12 weeks (SMD=-1.40; 95% CI: -1.97, -0.82; P<0.00001) of macrolide therapy. Similarly, findings for CT scores showed significant improvements in CT scores compared to baseline after 12 weeks' treatment (MD=-5.81; 95% CI: -8.10, -3.52; P<0.00001) in cohort trials. CONCLUSIONS: Macrolide therapy can significantly improve endoscopic and CT scores in CRS patients, compared to baseline. Further well-designed studies are needed to confirm the efficacy and safety of macrolides in CRS treatment.
BACKGROUND: The purpose of this study was to systematically assess the subjective and objective outcomes of macrolide therapy for chronic rhinosinusitis (CRS). METHODS: PubMed, Embase and Cochrane databases were searched for clinical trials detailing the effects of macrolide therapy in patients with CRS and published up to December 2017. Sino-Nasal Outcome Test (SNOT), endoscopic scores and computed tomography scans (CT) scores were assessed by mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval. Subgroup analyses were performed to evaluate the source of heterogeneity according to study design and geographic locations. I2 metric was used to assess the heterogeneity. RESULTS: Seven randomised clinical trials (RCTs) and four cohort trials meeting pre-determined selection criteria were enrolled in this meta-analysis. Assessment of the findings for SNOT after 12 weeks' macrolide treatment demonstrated a significant improvement in subgroup of trials in Asian patients (SMD =-0.51; 95% CI: -0.96, -0.02; P=0.04), but not in non-Asians (SMD =-0.01; 95% CI: -0.65, 0.63; P=0.98). At 12 or 24 weeks' visit no significant difference in SNOT was noted compared with control group, either in RCTs or cohort trials subgroups. However, findings for endoscopic scores were found to be significantly improved compared to placebo in the subgroup of non-RCT studies after 8 weeks (SMD =-0.77; 95% CI: -1.07, -0.46; P<0.00001) and 12 weeks (SMD=-1.40; 95% CI: -1.97, -0.82; P<0.00001) of macrolide therapy. Similarly, findings for CT scores showed significant improvements in CT scores compared to baseline after 12 weeks' treatment (MD=-5.81; 95% CI: -8.10, -3.52; P<0.00001) in cohort trials. CONCLUSIONS: Macrolide therapy can significantly improve endoscopic and CT scores in CRS patients, compared to baseline. Further well-designed studies are needed to confirm the efficacy and safety of macrolides in CRS treatment.
Authors: W J Videler; L Badia; R J Harvey; S Gane; C Georgalas; F W van der Meulen; D J Menger; M T Lehtonen; S K Toppila-Salmi; S I Vento; M Hytönen; P W Hellings; L Kalogjera; V J Lund; G Scadding; J Mullol; W J Fokkens Journal: Allergy Date: 2011-09-02 Impact factor: 13.146
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinol Suppl Date: 2012-03
Authors: Naweed I Chowdhury; Jess C Mace; Todd E Bodner; Jeremiah A Alt; Adam S Deconde; Joshua M Levy; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2017-10-20 Impact factor: 3.858
Authors: Karen Head; Lee Yee Chong; Patorn Piromchai; Claire Hopkins; Carl Philpott; Anne G M Schilder; Martin J Burton Journal: Cochrane Database Syst Rev Date: 2016-04-26
Authors: Alfonso Luca Pendolino; Foteini Stefania Koumpa; Henry Zhang; Samuel C Leong; Peter J Andrews Journal: Eur Arch Otorhinolaryngol Date: 2020-04-29 Impact factor: 2.503